![James Daniel Guylain Priour](https://cdn.zonebourse.com/static/resize/768/576//static/images/insiders/unknown.png)
James Daniel Guylain Priour
Keine laufenden Positionen mehr
Karriereverlauf von James Daniel Guylain Priour
Ehemalige bekannte Positionen von James Daniel Guylain Priour
Unternehmen | Position | Beginn | Ende |
---|---|---|---|
Zymeworks BC, Inc.
![]() Zymeworks BC, Inc. BiotechnologyHealth Technology Zymeworks BC, Inc. is a clinical-stage biopharmaceutical company engaged in the discovery, development, and commercialization of biotherapeutics. Its product, ZW25 and ZW49, are a bispecific antibody that cans two non-overlapping epitopes. The company was founded by Anthony Fejes, J. Haig deB Farris, Nick Bedford, Ali Tehrani and Andrew S. Wright on September 8, 2003 and is headquartered in Vancouver, Canada. | Corporate Officer/Principal | - | 19.01.2022 |
Amgen Australia Pty Ltd. | Corporate Officer/Principal | 01.01.2012 | - |
Amgen France | Corporate Officer/Principal | 01.01.2009 | - |
BRISTOL-MYERS SQUIBB COMPANY | Corporate Officer/Principal | 01.01.2006 | - |
PROCTER & GAMBLE COMPANY | Vertrieb & Marketing | 01.01.1992 | - |
Ausbildung von James Daniel Guylain Priour
NEOMA Business School | Masters Business Admin |
Statistik
International
Vereinigte Staaten | 3 |
Frankreich | 3 |
Kanada | 2 |
Operativ
Corporate Officer/Principal | 4 |
Sales & Marketing | 1 |
Masters Business Admin | 1 |
Sektoral
Health Technology | 3 |
Consumer Non-Durables | 2 |
Consumer Services | 2 |
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Unternehmensverbindungen
Börsennotierte Unternehmen | 2 |
---|---|
BRISTOL-MYERS SQUIBB COMPANY | Health Technology |
PROCTER & GAMBLE COMPANY | Consumer Non-Durables |
Private Unternehmen | 3 |
---|---|
Zymeworks BC, Inc.
![]() Zymeworks BC, Inc. BiotechnologyHealth Technology Zymeworks BC, Inc. is a clinical-stage biopharmaceutical company engaged in the discovery, development, and commercialization of biotherapeutics. Its product, ZW25 and ZW49, are a bispecific antibody that cans two non-overlapping epitopes. The company was founded by Anthony Fejes, J. Haig deB Farris, Nick Bedford, Ali Tehrani and Andrew S. Wright on September 8, 2003 and is headquartered in Vancouver, Canada. | Health Technology |
Amgen France | |
Amgen Australia Pty Ltd. |